Acetyl Hexapeptide-3, Acetyl Hexapeptide-8
Evidence Grade D — Primarily preclinical. 20 published studies, mostly animal models. 6 registered clinical trials.
Argireline is a synthetic hexapeptide widely used in cosmetic skincare as a topical alternative to Botox for reducing expression lines. Marketed as 'Acetyl Hexapeptide-8', it appears in numerous anti-ageing creams and serums. It has no pharmaceutical approval. A key scientific question is whether enough peptide can penetrate intact skin to reach the muscle junctions where it would need to act.
20 published studies: 9 human, 2 animal, 3 in-vitro, 2 reviews
Argireline has no pharmaceutical authorisation. It is widely available as a cosmetic ingredient in over-the-counter skincare products. Small industry-sponsored studies have reported wrinkle depth reductions of 17–30% with topical application.
The key scientific question is whether sufficient peptide penetrates intact skin to reach neuromuscular junctions and produce a meaningful effect. The molecule's size exceeds the conventional limit for transdermal absorption. Argireline's cosmetic use in formulated skincare products represents a fundamentally different risk profile from injectable use.
Research suggests Argireline inhibits the SNARE complex — the molecular machinery that nerve endings use to release the signalling molecule acetylcholine at muscle junctions. By reducing acetylcholine release, the theory is that facial muscles contract less strongly, reducing expression lines. A critical limitation is that at nearly 889 Da, the molecule exceeds the generally accepted size limit for skin penetration (500 Da), and studies report very low absorption rates.
Research suggests small industry-sponsored studies have reported wrinkle depth reductions of 17-30% with topical application. The molecular mechanism (inhibiting the SNARE complex that controls muscle signalling) is well-characterised in laboratory settings. However, a 2025 systematic review found that no dedicated double-blind trials exist. The molecule exceeds the generally accepted size limit for skin penetration (889 Da versus the 500 Da threshold), and studies report very low absorption rates (under 0.2%). Combined with its 4,286-fold lower potency compared to botulinum toxin, serious questions remain about whether biologically meaningful concentrations reach the target site through topical application alone.
A Clinical Trial to Evaluate the Effects of an Eye Serum on Improving the Appearance of the Periorbital Area
Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream
Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin
Acetyl Hexapeptide-8 for Blepharospasm
A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base. The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
FOXO4-DRI has no marketing authorisation. No human clinical trials have been conducted. The evidence comes from a single high-profile publication (Cell, 2017) demonstrating effects in three mouse models. The senolytic field is an active area of pharmaceutical research, but FOXO4-DRI faces significant challenges for clinical translation, including its large size (46 amino acids), manufacturing complexity, and the absence of human pharmacokinetic or safety data. Products available through unregulated channels — which would need to reliably synthesise a 46-amino-acid all-D-amino-acid peptide — face exceptional quality assurance challenges.
